{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit is not applicable due an to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"34.5","upperLimit":"NA","value":"77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"PFS is defined as the duration of time from start of study treatment to time of progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"First participant received: CFZ 27mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Second participant received: CFZ 36mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Third participant received: CFZ 36mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fourth participant received: CFZ 45mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fifth participant and all other participants received: CFZ 56mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg.\n\nData was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.","id":"OG000","title":"CFZ With Bendamustine and Dexamethasone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 6.5 Years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}